Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?

Novo Nordisk, which pioneered GLP-1 weight-loss drugs but lost market leadership to Eli Lilly, is attempting a comeback through product innovation. The company has launched a pill version of Wegovy and partnered with Vivani Medical to develop an implant that could deliver the drug once or twice yearly, potentially revolutionizing convenience in the GLP-1 market. While Eli Lilly maintains a stronger market position and higher valuation, Novo Nordisk's continued innovation could help it regain competitive ground.